Clinical Trials
-
Tackling The Challenges Of A Rare-Disease Clinical Trial
4/7/2017
Regulatory agencies today are looking for Phase 3 trials to demonstrate a reduction in mortality as well as greater patient mobility. Unfortunately, Phase 3 trials also cost a lot of money to run, making them a challenge for small biotech firms.
-
Janssen Turns Clinical Data Over To Patients
4/7/2017
Andreas Koester, MD, Ph.D., global head, R&D operations innovation at Janssen, discusses how the company is attempting to make patient data available to participants while a clinical trial is underway.
-
How Patients Will Revolutionize Next-Generation Clinical Research
2/1/2017
Often when we think about inefficiencies in the clinical trial process, we focus on the role of the sponsor or CRO, a particular aspect of the value chain, or new technologies that promote data sharing and faster decision making. While these are critical aspects that drive day-to-day operations, there is another aspect of the value chain that we may be neglecting: the patient side.
-
Considerations For The Use Of Wearables In Clinical Trials
2/1/2017
With wearables, we now have the means to innovate the “where” and the “how” of patient data capture, creating a 24-hour digital map of physical behaviors.
-
Janssen Uses Trial Simulations To Capture Patient Concerns
1/1/2017
Bert Hartog, Ph.D., innovation leader, in R&D Operations Innovation at Janssen Research & Development, has a plan in place to make trials more patient-friendly. Janssen’s goal is to incorporate the patient voice into clinical research, make patients a partner in the research process, and ensure all future collaborations are a two-way street.
-
Cancer Immunotherapy - Simpler Or More Complex?
9/1/2016
A summary of the issues that recently fired up the IO field.
-
Leveraging China Innovation For Worldwide Growth
7/1/2016
When you talk to Dr. Mireille Gillings, the founder and executive chair of HUYA Bioscience International, her enthusiasm and passion for drug development is clearly evident.
-
Developing New Therapeutics For Progressive MS
6/1/2016
This is the concluding installment of our three-part series on new therapeutic mechanisms for neurodegenerative diseases. Here, as in the first two parts, we have brought together a “virtual roundtable” comparing the views of key scientific opinion leaders with some of the companies developing new therapeutics for progressive MS. (See Part One, “Aiming at Alzheimer’s,” March 2016, and Part Two, “Parsing Out Parkinson’s,” April 2016.)
-
Technology Will Continue To Drive Efficiencies In Clinical Trials
12/1/2015
Our expert panel predicts mobile technologies are poised to gain traction in clinical trials next year. Other hot trends in the clinical space include more focus on patient-centricity and greater adoption of risk-based monitoring and EHRs.
-
How One Biopharma Improved Patient & Clinical Site Relationships
11/1/2015
Eileen Daniel, executive director of clinical operations at Nektar Therapeutics, always felt there were ways the clinical trial planning process could be improved.